On March 11, DS Securities resumed coverage of Pharmicell, setting a target price of 25,000 won and a 'Buy' investment rating.


Pharmicell reported consolidated sales of 114 billion won last year, up 75.8% from the previous year, and operating profit of 34.3 billion won, which surged 637.6% during the same period. Of this, chemical business sales nearly doubled to 111.5 billion won, and most of this growth was driven by sales to Doosan Electronic BG. Soohyun Kim, an analyst at DS Securities, commented, "Compared to our initial forecasts at the beginning of last year, sales fell short by 20 billion won, while operating profit met expectations and the profitability of resin and hardener products was much better than anticipated." Kim added, "Sales of resin and hardener products to Doosan Electronic BG are estimated at 64.8 billion won, accounting for 58% of total sales."


[Click eStock] "Pharmicell Anticipates Growth in Chemical Business Sales to Doosan" View original image

The analyst projected that Pharmicell's growth will accelerate further starting this year. Kim stated, "The positive volume effect from the transition from Nvidia's GB200 to GB300 is continuing, and that momentum is expected to be even stronger in the first quarter of this year." Kim also noted, "Some sales also appear to include samples related to bilirubin." He continued, "Average monthly sales to Doosan Electronic BG are expected to surge from 5 billion won last year to 9 billion won per month in the first half of this year, indicating explosive growth from the beginning of the year." Since these figures reflect the period before the launch of the bilirubin product, expectations for improved performance in the second half are rising.


Kim further forecast that Pharmicell’s annual sales to Doosan will grow from 64.8 billion won last year to over 110 billion won this year. In terms of profitability, sales of hardener products—which are 50% more profitable than resin—are expected to increase, leading to overall improved profitability. Hardener sales to Doosan are anticipated to rise from 32.4 billion won last year to about 60 billion won this year.


Production capacity is also expected to improve. Kim explained, "With Doosan reviewing additional capacity expansion, Pharmicell has completed approval for process improvements to respond to demand, enabling a 20–30% increase in production volume compared to the existing level." Kim added, "The third plant, scheduled for completion in September, will begin operations in 2027, and its sales capacity will be 200 billion won, which is double the combined capacity of Plants 1 and 2."



Meanwhile, regarding the recent decline in Pharmicell's stock price amid falling oil prices, Kim viewed it as 'noise unrelated to fundamentals.' He stated, "The correlation with fundamentals is low," and explained, "The company's main raw material, sebacic acid, is based on castor oil and has little direct price linkage with crude oil." Kim emphasized that "the key variables for performance momentum are not oil prices, but demand for AI servers and the direction of capacity expansion at Doosan Electronic BG."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing